A Connecticut federal judge has sided with the US Department of Health and Human Services (HHS) in Boehringer Ingelheim's challenge to Medicare’s drug price negotiation programme, rejecting
Chronic obstructive pulmonary disease (COPD) has seen no new therapies brought to market for around 10 years – and now there have been two in the space of a couple of weeks.
Eli Lilly finally has FDA approval for its amyloid-busting Alzheimer’s disease therapy donanemab and will launch it at a cost it claims could deliver savings compared to a rival therapy fro
Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to cu
Apellis Pharma has said it will seek a re-evaluation of its marketing application for Syfovre for eye disease geographic atrophy (GA) after the EMA’s human medicines committee turned it dow
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.